I saw this on fnarena. Not really any surprise, but the downgrade may have worried some. They have had a $4 target since August last year.
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 0 Macquarie 08/06/2018 3 Downgrade to Neutral from Outperform $4.00 7.82% 1
- COMMENTARYCEO, Mick McMahon, will be stepping down at the FY18 results. The transition has come earlier than Macquarie expected. The share price reaction has reflected this development and the strong regard in which the CEO is held, the broker suggests.There is no change to the FY18 outlook, with feed cost increases being recovered via prices, both under contract and on the spot market.While valuation is undemanding, the broker suggests uncertainty over new management is likely to persist until a permanent CEO arrives and there is clarity on the FY19 outlook.Rating is downgraded to Neutral from Outperform. $4.00 target retained.
- Forums
- ASX - By Stock
- Ann: Ingham's CEO Transition
ING
inghams group limited
Add to My Watchlist
0.28%
!
$3.54

I saw this on fnarena. Not really any surprise, but the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$3.54 |
Change
0.010(0.28%) |
Mkt cap ! $1.312B |
Open | High | Low | Value | Volume |
$3.60 | $3.60 | $3.52 | $1.295M | 366.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
57 | 16915 | $3.53 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.54 | 27639 | 68 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
60 | 18525 | 3.530 |
27 | 31183 | 3.520 |
18 | 18794 | 3.510 |
18 | 39273 | 3.500 |
13 | 18468 | 3.490 |
Price($) | Vol. | No. |
---|---|---|
3.540 | 19034 | 62 |
3.550 | 36813 | 38 |
3.560 | 21313 | 17 |
3.570 | 8601 | 12 |
3.580 | 35063 | 15 |
Last trade - 15.21pm 04/07/2025 (20 minute delay) ? |
Featured News
ING (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online